We are live on ! Find out more
TS

Thomas Steyer Farallon Capital Management

AUM $21.7B
1-Year Est. Return 79.24%
 

Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.

This Fund
S&P 500
This Quarter Est. Return
+19.41%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$16.6B
AUM Growth
+$2.17B
Cap. Flow
-$81M
Cap. Flow %
-0.49%
Top 10 Hldgs %
31.47%
Holding
166
New
39
Increased
28
Reduced
33
Closed
30

Top Buys

Rank Stock Value
1
ARMK icon
Aramark
ARMK
+$366M
2
XLNX
Xilinx Inc
XLNX
+$332M
3
RTX icon
RTX Corp
RTX
+$299M
4
ALXN
Alexion Pharmaceuticals
ALXN
+$289M
5
AVGO icon
Broadcom
AVGO
+$243M

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$498M
2
INFO
IHS Markit Ltd. Common Shares
INFO
+$299M
3
ABBV icon
AbbVie
ABBV
+$298M
4
PANW icon
Palo Alto Networks
PANW
+$217M
5
BMY icon
Bristol-Myers Squibb
BMY
+$215M

Sector Composition

Rank Sector Weight
1 Healthcare 38.5%
2 Technology 14.31%
3 Communication Services 13.23%
4 Financials 10.05%
5 Industrials 8.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AUPH icon
126
Aurinia Pharmaceuticals
AUPH
$2.22B
– –
-1,000,000
Closed -$14.7M
CI icon
127
Cigna
CI
$73.3B
– –
-502,231
Closed -$85.1M
CMPS
128
Compass Pathways
CMPS
$1.85B
– –
-362,940
Closed -$12.7M
CRDF icon
129
Cardiff Oncology
CRDF
$68.5M
– –
-200,000
Closed -$2.84M
DYN icon
130
Dyne Therapeutics
DYN
$4.87B
– –
-200,000
Closed -$4.04M
EMB icon
131
PUT
iShares JPMorgan USD Emerging Markets Bond ETF
EMB
$14.7B
– –
-288,900
Closed -$320M
EQIX icon
132
Equinix
EQIX
$105B
– –
-200,164
Closed -$152M
GD icon
133
General Dynamics
GD
$104B
– –
-1,277,107
Closed -$177M
LQDA icon
134
Liquidia Corp
LQDA
$6.14B
– –
-1,865,350
Closed -$9.18M
NVCR icon
135
NovoCure
NVCR
$1.99B
– –
-725,000
Closed -$80.7M
PANW icon
136
Palo Alto Networks
PANW
$292B
– –
-5,327,352
Closed -$217M
RCUS icon
137
Arcus Biosciences
RCUS
$3.86B
– –
-550,000
Closed -$9.43M
TARA icon
138
Protara Therapeutics
TARA
$228M
– –
-425,000
Closed -$7.15M
ZNTL icon
139
Zentalis Pharmaceuticals
ZNTL
$363M
– –
-991,174
Closed -$32.4M
FUSN
140
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
– –
-187,600
Closed -$2.25M
NVTA
141
DELISTED
Invitae Corporation
NVTA
– –
-593,472
Closed -$25.7M
BRMK
142
CALL
DELISTED
Broadmark Realty Capital Inc. Common Stock
BRMK
– –
-2,391,536
Closed -$23.6M
QTNT
143
DELISTED
Quotient Limited Ordinary Shares
QTNT
– –
-15,625
Closed -$3.21M
GBT
144
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-600,000
Closed -$33.1M
INFO
145
DELISTED
IHS Markit Ltd. Common Shares
INFO
– –
-3,812,944
Closed -$299M
NAV
146
DELISTED
Navistar International
NAV
– –
-276,600
Closed -$12M
PAND
147
DELISTED
Pandion Therapeutics Inc. Common Stock
PAND
– –
-100,000
Closed -$1.15M
MYOK
148
DELISTED
MyoKardia, Inc. Common Stock
MYOK
– –
-1,225,000
Closed -$167M
WMGI
149
DELISTED
Wright Medical Group Inc
WMGI
– –
-5,097,546
Closed -$156M
LVGO
150
DELISTED
Livongo Health, Inc. Common Stock
LVGO
– –
-830,000
Closed -$116M
3 4 5
6
7

Similar funds

BG
Bahl & Gaynor Cincinnati, Ohio $21.7B AUM 30.58% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return
CHP
Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Thomas Steyer's Q4 2020 Portfolio in Review

As of Q4 2020, Thomas Steyer held 166 positions worth $16.6B, up 15% from $14.5B the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Thomas Steyer's Q4 2020 filing shows 39 new, 28 increased, 33 reduced and 30 closed positions. Its largest new stake was Aramark: 15,268,169 shares worth $424M. The largest sale was Immunomedics Inc, an estimated $498M.

By sector, the portfolio is most concentrated in Healthcare at 39% of assets, down from 45% a quarter earlier, followed by Technology and Communication Services.

  • Thomas Steyer's largest Q4 2020 buy was Aramark: 15,268,169 shares worth $424M.
  • Thomas Steyer added most to Willis Towers Watson in Q4 2020, an estimated $188M increase.
  • Thomas Steyer's biggest Q4 2020 reduction was AbbVie, cutting an estimated $298M.
  • Thomas Steyer fully exited Immunomedics Inc in Q4 2020, selling an estimated $498M.
  • Thomas Steyer's ten largest holdings make up 31% of its $16.6B portfolio in Q4 2020.
  • Thomas Steyer opened 39 new positions and closed 30 in Q4 2020.
  • Thomas Steyer's portfolio value rose 15% quarter-over-quarter to $16.6B.

Based on Farallon Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.